The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial
Open accessAbstract
The aim of the present study was to investigate the efficacy of infliximab for the treatment of extrapulmonary sarcoidosis. A prospective, randomised, double-blind, placebo-controlled trial was conducted, with infliximab at 3 and 5 mg·kg−1 body weight administered over 24 weeks. Extrapulmonary organ severity was determined by a novel severity tool (extrapulmonary physician organ severity tool; ePOST) with an adjustment for the number of organs involved (ePOSTadj). In total, 138 patients enrolled in the trial of infliximab versus placebo for the treatment of chronic corticosteroid-dependent pulmonary sarcoidosis. The baseline severity of extrapulmonary organ involvement, as measured by ePOST, was similar across treatment groups. After 24 weeks of drug-therapy study, the change from baseline to week 24 in ePOST was greater for the combined infliximab group compared with the placebo group. After adjustment for the number of extrapulmonary organs involved, the improvement in ePOSTadj observed in the combined infliximab group was also greater than that observed in placebo-treated patients, after 24 weeks of therapy. The improvements in ePOST and ePOSTadj were not maintained during a subsequent 24-week washout period. Infliximab may be beneficial compared with placebo in the treatment of extrapulmonary sarcoidosis in patients already receiving corticosteroids, as assessed by the severity tool described in the present study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
A Case Control Etiologic Study of Sarcoidosis: Environmental and Occupational Risk Factors
Newman, L. S., Rose, C. S., Bresnitz, E. A., Rossman, M. D., Barnard, J., Frederick, M., Terrin, M. L., Weinberger, S. E., Moller, D. R., McLennan, G., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200402-249oc · Cited by 801
Self-citationInfliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement
Baughman, R. P., Drent, M., Kavuru, M., Judson, M. A., Costabel, U., du Bois, R., Albera, C., Brutsche, M., Davis, G., Donohue, J. F., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-402oc · Cited by 714
Self-citationBinding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
Fletcher, C. M. (1960) · Medical Entomology and Zoology · Cited by 340
Diagnosis and Management of Neurological Sarcoidosis
Lower, E. E. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.16.1864 · Cited by 330
Treatment of Sarcoidosis With Infliximab
Doty, J. D., Mazur, J. E., & Judson, M. A. (2005) · Chest · doi:10.1378/chest.127.3.1064 · Cited by 312
Self-citationStandardized Questionaries on Respiratory Symptoms
(1960) · BMJ · doi:10.1136/bmj.2.5213.1665 · Cited by 295
Judson, M. A., Baughman, R. P., Teirstein, A. S., Ml, T., & Yeager, H. (1999) · PubMed · Cited by 284
Self-citationTreatment of chronic sarcoidosis with an azathioprine/prednisolone regimen
Muller-Quernheim, J., Kienast, K., Held, M., Pfeifer, S., & Costabel, U. (1999) · European Respiratory Journal · doi:10.1183/09031936.99.14511179 · Cited by 244
Self-citation
Cited by
ERS clinical practice guidelines on treatment of sarcoidosis
Baughman, R. P., Valeyre, D., Korsten, P., Mathioudakis, A. G., Wuyts, W. A., Wells, A., Rottoli, P., Nunes, H., Lower, E. E., Judson, M. A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04079-2020 · Cited by 629
Self-citationBirnie, D. H., Nery, P. B., Ha, A. C., & Beanlands, R. S. B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.605 · Cited by 569
A Concise Review of Pulmonary Sarcoidosis
Baughman, R. P., Culver, D. A., & Judson, M. A. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0865ci · Cited by 536
Self-citationJamilloux, Y., Cohen-Aubart, F., Chapelon-Abric, C., Maucort-Boulch, D., Marquet, A., Pérard, L., Bouillet, L., Deroux, A., Abad, S., Bielefeld, P., et al. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.03.005 · Cited by 98
Ribeiro Neto, M. L., Jellis, C. L., Joyce, E., Callahan, T. D., Hachamovitch, R., & Culver, D. A. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201902-119cme · Cited by 63
Metadata
- Authors
- Judson, M. A., Baughman, R. P., Costabel, U., Flavin, S., Lo, K. H., Kavuru, M. S., Drent, M., & the Centocor T48 Sarcoidosis investigators
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2008-02-06
- Volume
- 31
- Issue
- 6
- Pages
- 1189-1196
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2130860647
- Cited by
- 324
- References
- 21
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. https://app.cochat.ai/papers/10.1183/09031936.00051907
- The paper
- Judson, M. A., Baughman, R. P., Costabel, U., Flavin, S., Lo, K. H., Kavuru, M. S., Drent, M., & the Centocor T48 Sarcoidosis investigators. (2008). Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. European Respiratory Journal. https://doi.org/10.1183/09031936.00051907
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.